These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
☒
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
Morgan Group Holding Co.
|
|
(Exact name of Registrant as specified in its charter)
|
|
Delaware
|
13-4196940
|
|
|
(State of other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
401 Theodore Fremd Avenue, Rye, NY
|
10580
|
|
|
(Address of principle executive offices)
|
(Zip Code)
|
|
(914) 921-5216
|
|
(Registrant’s telephone number, including area code)
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.01 per share
|
MGHL
|
OTC Pink®
|
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
|
|
Non-accelerated filer ☒
|
Smaller reporting company ☒
|
Emerging growth company ☐
|
|
Class
|
Outstanding at April 30, 2020
|
|
|
Common Stock, $0.01 par value
|
60,009,005
|
|
PART I.
|
FINANCIAL INFORMATION
|
Page
|
|
Item 1.
|
Unaudited Condensed Consolidated Financial Statements
|
|
|
1
|
||
|
2
|
||
|
3
|
||
|
4
|
||
|
5
|
||
|
Item 2.
|
13
|
|
|
Item 3.
|
16
|
|
|
Item 4.
|
16
|
|
|
PART II.
|
OTHER INFORMATION *
|
|
|
Item 1.
|
17
|
|
|
Item 1A.
|
17
|
|
|
Item 6.
|
17
|
|
|
18
|
|
March 31,
2020
|
December 31,
2019
|
|||||||
|
ASSETS
|
||||||||
|
Cash and cash equivalents
|
$
|
5,668,869
|
$
|
6,587,097
|
||||
|
Receivables from brokers and clearing organizations
|
299,210
|
808,686
|
||||||
|
Receivables from affiliates
|
171,981
|
30,625
|
||||||
|
Deposits with clearing organizations
|
200,000
|
200,000
|
||||||
|
Income taxes receivable (including deferred tax asset of $11,498 and $2,930, respectively)
|
306,632
|
184,396
|
||||||
|
Fixed assets, net of accumulated depreciation of $31,472 and $28,435, respectively
|
41,418
|
44,456
|
||||||
|
Other assets
|
237,800
|
281,896
|
||||||
|
Total assets
|
$
|
6,925,910
|
$
|
8,137,156
|
||||
|
LIABILITIES AND EQUITY
|
||||||||
|
Compensation payable
|
$
|
342,220
|
$
|
709,663
|
||||
|
Payable to affiliates
|
220,588
|
985,632
|
||||||
|
Income tax payable
|
57,245
|
53,572
|
||||||
|
Accrued expenses and other liabilities
|
550,970
|
350,948
|
||||||
|
Total liabilities
|
1,171,023
|
2,099,815
|
||||||
|
Commitments and contingencies (Note 9)
|
|
|
||||||
|
Equity
|
||||||||
|
Common stock, $0.01 par value; 100,000,000 shares authorized and 60,009,005 shares issued and outstanding
|
600,091
|
600,091
|
||||||
|
Additional paid-in capital
|
53,292,090
|
53,292,090
|
||||||
|
Accumulated deficit
|
(48,137,294
|
)
|
(47,854,840
|
)
|
||||
|
Total equity
|
5,754,887
|
6,037,341
|
||||||
|
Total liabilities and equity
|
$
|
6,925,910
|
$
|
8,137,156
|
||||
|
Three Months Ended March 31,
|
||||||||
|
2020
|
2019
|
|||||||
|
Revenues
|
||||||||
|
Commissions
|
$
|
1,038,943
|
$
|
1,535,245
|
||||
|
Fees earned from affiliated entities pursuant to research services agreements
|
-
|
377,500
|
||||||
|
Principal transactions
|
(903
|
)
|
(80
|
)
|
||||
|
Dividends and interest
|
36,256
|
63,693
|
||||||
|
Underwriting fees
|
30,488
|
-
|
||||||
|
Sales manager fees
|
334,825
|
-
|
||||||
|
Other revenues
|
3,107
|
5,909
|
||||||
|
Total revenues
|
1,442,716
|
1,982,267
|
||||||
|
Expenses
|
||||||||
|
Compensation and related costs
|
1,143,433
|
2,478,892
|
||||||
|
Clearing charges
|
302,838
|
290,381
|
||||||
|
General and administrative
|
311,109
|
324,842
|
||||||
|
Occupancy and equipment
|
104,441
|
195,842
|
||||||
|
Total expenses
|
1,861,821
|
3,289,957
|
||||||
|
Loss before income tax benefit
|
(419,105
|
)
|
(1,307,690
|
)
|
||||
|
Income tax benefit
|
(136,651
|
)
|
(267,048
|
)
|
||||
|
Net loss
|
$
|
(282,454
|
)
|
$
|
(1,040,642
|
)
|
||
|
Net loss per share
|
||||||||
|
Basic and diluted
|
$
|
(0.00
|
)
|
$
|
(0.02
|
)
|
||
|
Weighted average shares outstanding:
|
||||||||
|
Basic and diluted
|
60,009,005
|
54,859,055
|
||||||
|
Shares
|
Common
Stock
|
Additional
Paid-in
Capital
|
Accumulated
Deficit
|
Total
|
||||||||||||||||
|
Balance at December 31, 2019
|
60,009,055
|
$
|
600,091
|
$
|
53,292,090
|
$
|
(47,854,840
|
)
|
$
|
6,037,341
|
||||||||||
|
Net loss
|
-
|
-
|
-
|
(282,454
|
)
|
(282,454
|
)
|
|||||||||||||
|
Balance at March 31, 2020
|
60,009,055
|
600,091
|
53,292,090
|
(48,137,294
|
)
|
5,754,887
|
||||||||||||||
|
Shares
|
Common
Stock
|
Additional
Paid-in
Capital
|
Accumulated
Deficit
|
Total
|
||||||||||||||||
|
Balance at December 31, 2018
|
54,859,055
|
$
|
548,591
|
$
|
55,717,701
|
$
|
(45,948,248
|
)
|
$
|
10,318,044
|
||||||||||
|
Net loss
|
-
|
-
|
-
|
(1,040,642
|
)
|
(1,040,642
|
)
|
|||||||||||||
|
Balance at March 31, 2019
|
54,859,055
|
548,591
|
55,717,701
|
(46,988,890
|
)
|
9,277,402
|
||||||||||||||
|
Three months ended March 31,
|
||||||||
|
2020
|
2019
|
|||||||
|
Cash flows from operating activities:
|
||||||||
|
Net loss
|
$
|
(282,454
|
)
|
$
|
(1,040,642
|
)
|
||
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
|
Depreciation
|
3,038
|
3,217
|
||||||
|
Deferred income tax, net
|
(8,568
|
)
|
280,931
|
|||||
|
(Increase)/decrease in assets:
|
||||||||
|
Receivables from brokers and clearing organizations
|
509,476
|
(228,589
|
)
|
|||||
|
Receivables from affiliates
|
(141,356
|
)
|
(57,643
|
)
|
||||
|
Income taxes receivable
|
(113,668
|
)
|
500
|
|||||
|
Other assets
|
44,096
|
40,484
|
||||||
|
Increase/(decrease) in liabilities:
|
||||||||
|
Payable to affiliates
|
(765,044
|
)
|
33,570
|
|||||
|
Income taxes payable
|
3,673
|
-
|
||||||
|
Compensation payable
|
(367,443
|
)
|
(891,546
|
)
|
||||
|
Accrued expenses and other liabilities
|
200,022
|
35,600
|
||||||
|
Total adjustments
|
(635,774
|
)
|
(783,476
|
)
|
||||
|
Net cash used in operating activities
|
(918,228
|
)
|
(1,824,118
|
)
|
||||
|
Net decrease in cash and cash equivalents and restricted cash
|
(918,228
|
)
|
(1,824,118
|
)
|
||||
|
Cash, cash equivalents, and restricted cash at beginning of period
|
6,787,097
|
11,530,705
|
||||||
|
Cash, cash equivalents, and restricted cash at end of period
|
$
|
5,868,869
|
$
|
9,706,587
|
||||
|
Supplemental disclosures of cash flow information:
|
||||||||
|
Cash received from Associated Capital Group, Inc. for income taxes
|
$
|
18,087
|
$
|
543,153
|
||||
|
Reconciliation to cash, cash equivalents, and restricted cash
|
||||||||
|
Cash and cash equivalents
|
$
|
5,668,869
|
$
|
9,506,587
|
||||
|
Restricted cash: deposits from clearing organizations
|
200,000
|
200,000
|
||||||
|
Cash, cash equivalents, and restricted cash
|
$
|
5,868,869
|
$
|
9,706,587
|
||||
|
|
Three months ended March 31,
|
|||||||
|
|
2020
|
2019
|
||||||
|
Commissions
|
$
|
936,784
|
$
|
1,426,235
|
||||
|
Hard dollar payments
|
102,159
|
109,010
|
||||||
|
1,038,943
|
1,535,245
|
|||||||
|
Research services
|
-
|
377,500
|
||||||
|
Underwriting fees
|
30,488
|
-
|
||||||
|
Sales manager fees
|
334,825
|
-
|
||||||
|
$
|
1,404,256
|
$
|
1,912,745
|
|||||
|
-
|
Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 1 assets include cash equivalents.
|
|
-
|
Level 2 inputs utilize inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs
include quoted prices for similar assets and liabilities in active markets and inputs other than quoted prices that are observable for the asset or liability, such as interest rates and yield curves that are observable at commonly
quoted intervals.
|
|
-
|
Level 3 inputs are unobservable inputs for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. These
assets include infrequently traded common stocks.
|
|
Assets
|
Quoted Prices in Active
Markets for Identical
Assets (Level 1)
|
Significant Other
Observable
Inputs (Level 2)
|
Significant
Unobservable
Inputs (Level 3)
|
Total
|
||||||||||||
|
Cash equivalents
|
$
|
5,661,750
|
$
|
-
|
$
|
-
|
$
|
5,661,750
|
||||||||
|
Total assets at fair value
|
$
|
5,661,750
|
$
|
-
|
$
|
-
|
$
|
5,661,750
|
||||||||
|
Assets
|
Quoted Prices in Active
Markets for Identical
Assets (Level 1)
|
Significant Other
Observable
Inputs (Level 2)
|
Significant
Unobservable
Inputs (Level 3)
|
Total
|
||||||||||||
|
Cash equivalents
|
$
|
6,579,577
|
$
|
-
|
$
|
-
|
$
|
6,579,577
|
||||||||
|
Total assets at fair value
|
$
|
6,579,577
|
$
|
-
|
$
|
-
|
$
|
6,579,577
|
||||||||
|
Three Months Ended March 31,
|
||||||||
|
2020
|
2019
|
|||||||
|
Basic and diluted:
|
||||||||
|
Net loss attributable to shareholders
|
$
|
(282,454
|
)
|
$
|
(1,040,642
|
)
|
||
|
Weighted average shares outstanding
|
60,009,005
|
54,859,055
|
||||||
|
Basic and diluted net loss per share
|
$
|
(0.00
|
)
|
$
|
(0.02
|
)
|
||
|
Three Months Ended March 31,
|
||||||||
|
2020
|
2019
|
|||||||
|
Revenues
|
||||||||
|
Commissions
|
$
|
1,039
|
$
|
1,535
|
||||
|
Fees earned from affiliated entities pursuant to research services agreements
|
-
|
378
|
||||||
|
Principal transactions
|
(1
|
)
|
(0
|
)
|
||||
|
Dividends and interest
|
36
|
64
|
||||||
|
Underwriting fees
|
30
|
-
|
||||||
|
Sales manager fees
|
335
|
-
|
||||||
|
Other revenues
|
3
|
6
|
||||||
|
Total revenues
|
1,443
|
1,982
|
||||||
|
Expenses
|
||||||||
|
Compensation and related costs
|
1,143
|
2,479
|
||||||
|
Clearing charges
|
303
|
290
|
||||||
|
General and administrative
|
311
|
325
|
||||||
|
Occupancy and equipment
|
104
|
196
|
||||||
|
Total expenses
|
1,862
|
3,290
|
||||||
|
Loss before income tax benefit
|
(419
|
)
|
(1,308
|
)
|
||||
|
Income tax benefit
|
(137
|
)
|
(267
|
)
|
||||
|
Net loss
|
$
|
(282
|
)
|
$
|
(1,041
|
)
|
||
|
Net loss per share
|
||||||||
|
Basic and diluted
|
$
|
(0.00
|
)
|
$
|
(0.02
|
)
|
||
|
Three Months Ended March 31,
|
Increase (Decrease)
|
|||||||||||||||
|
2020
|
2019
|
$ |
|
%
|
||||||||||||
|
Commissions
|
$
|
937
|
$
|
1,426
|
$
|
(489
|
)
|
-34.3
|
%
|
|||||||
|
Hard dollar payments
|
102
|
109
|
(7
|
)
|
-6.4
|
%
|
||||||||||
|
1,039
|
1,535
|
$
|
(496
|
)
|
-32.3
|
%
|
||||||||||
|
Research services
|
-
|
378
|
(378
|
)
|
-100.0
|
%
|
||||||||||
|
Underwriting fees
|
30
|
-
|
30
|
n/a
|
||||||||||||
|
Sales manager fees
|
335
|
-
|
335
|
n/a
|
||||||||||||
|
Total
|
$
|
1,404
|
$
|
1,913
|
$
|
(509
|
)
|
-26.6
|
%
|
|||||||
|
Three Months Ended March 31,
|
||||||||
|
2020
|
2019
|
|||||||
|
Cash flows provided by (used in):
|
|
|
|
|
|
|
||
|
Operating activities
|
$ |
(918
|
)
|
$
|
(1,824
|
)
|
||
|
Net decrease in cash and cash equivalents
|
(918
|
)
|
(1,824
|
)
|
||||
|
Cash and cash equivalents at beginning of period
|
6,587
|
11,331
|
||||||
|
Cash and cash equivalents at end of period
|
$
|
5,669
|
$
|
9,507
|
||||
| ITEM 3. |
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
| ITEM 4. |
CONTROLS AND PROCEDURES
|
| ITEM 1. |
LEGAL PROCEEDINGS
|
| ITEM 1A. |
RISK FACTORS
|
|
Certification of CEO pursuant to Rule 13a-14(a).
|
||
|
Certification of CAO pursuant to Rule 13a-14(a).
|
||
|
Certification of CEO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
||
|
Certification of CAO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.
|
||
|
101.INS
|
|
XBRL Instance Document
|
|
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
|
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|